Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
8.60
-0.20 (-2.27%)
At close: Jul 20, 2026, 4:00 PM EDT
8.59
-0.01 (-0.12%)
After-hours: Jul 20, 2026, 7:34 PM EDT
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$723,800
Profits / Employee
$27,605
Market Cap
1.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,796 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Collegium Pharmaceutical | 423 |
XERS News
- 18 days ago - CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 18 days ago - Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 20 days ago - Xeris Biopharma appoints CEO John Shannon as chair of the board - TheFly
- 20 days ago - Xeris Announces Updates to Its Board of Directors - Business Wire
- 5 weeks ago - Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® - Business Wire
- 5 weeks ago - Xeris Biopharma announces private exchange of convertible notes - TheFly
- 5 weeks ago - Xeris Biopharma Announces Private Exchange of Convertible Notes - Business Wire
- 6 weeks ago - Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts